Acasunlimab

Cat. No.: HY-P99419

CAS No.: 2253937-12-9

Target: PD-1/PD-L1

Pathway: Immunology/Inflammation

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer[1][2].

In Vitro

Acasunlimab (GEN1046; 0.001-1 μM; 0-525 min) promotes interactions between dendritic cells and T cells and enhances T-cell activation[1].

Acasunlimab (0.001-1 μM; 48 h; PD-L1$^+$ Tumor Cells) induces dose-dependent, conditional T-cell proliferation and cytokine production and enhances antigen-specific T-cell–mediated cytotoxicity[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Acasunlimab (GEN1046; 5 mg/kg; twice weekly for three cycles) has antitumor activity and inhibits tumor growth in double knock-in (dKI) transgenic C57BL/6 mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Double knock-in (dKI) transgenic C57BL/6 mice[1]
Dosage:	5 mg/kg
Administration:	Intravenous injection; twice weekly for three cycles
Result:	Had antitumor activity in double knock-in (dKI) transgenic C57BL/6 mice.

REFERENCES

[1]. Muik A, et, al. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discov. 2022 May 2;12(5):1248-1265.

[2]. Gao Y, et, al. Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates. FEBS Open Bio. 2022 Dec;12(12):2166-2178.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA